90 related articles for article (PubMed ID: 19042941)
1. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension.
Duffels MG; Hardziyenka M; Surie S; de Bruin-Bon RH; Hoendermis ES; van Dijk AP; Bouma BJ; Tan HL; Berger RM; Bresser P; Mulder BJ
Eur J Echocardiogr; 2009 May; 10(3):433-8. PubMed ID: 19042941
[TBL] [Abstract][Full Text] [Related]
2. A comparison of echocardiographic variables of right ventricular function with exercise capacity after bosentan treatment in patients with pulmonary arterial hypertension: Results from a multicenter, prospective, cohort study.
Kim H; Bae Lee J; Park JH; Yoo BS; Son JW; Yang DH; Lee BR
J Clin Ultrasound; 2017 Jan; 45(1):28-34. PubMed ID: 27619758
[TBL] [Abstract][Full Text] [Related]
3. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension.
Surie S; Reesink HJ; Marcus JT; van der Plas MN; Kloek JJ; Vonk-Noordegraaf A; Bresser P
Clin Cardiol; 2013 Nov; 36(11):698-703. PubMed ID: 24037998
[TBL] [Abstract][Full Text] [Related]
4. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.
Galiè N; Hinderliter AL; Torbicki A; Fourme T; Simonneau G; Pulido T; Espinola-Zavaleta N; Rocchi G; Manes A; Frantz R; Kurzyna M; Nagueh SF; Barst R; Channick R; Dujardin K; Kronenberg A; Leconte I; Rainisio M; Rubin L
J Am Coll Cardiol; 2003 Apr; 41(8):1380-6. PubMed ID: 12706935
[TBL] [Abstract][Full Text] [Related]
5. Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension.
Chin KM; Kingman M; de Lemos JA; Warner JJ; Reimold S; Peshock R; Torres F
Am J Cardiol; 2008 Jun; 101(11):1669-72. PubMed ID: 18489949
[TBL] [Abstract][Full Text] [Related]
6. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.
Seyfarth HJ; Pankau H; Hammerschmidt S; Schauer J; Wirtz H; Winkler J
Chest; 2005 Aug; 128(2):709-13. PubMed ID: 16100158
[TBL] [Abstract][Full Text] [Related]
7. Correlation between right ventricular indices and clinical improvement in epoprostenol treated pulmonary hypertension patients.
Nath J; Demarco T; Hourigan L; Heidenreich PA; Foster E
Echocardiography; 2005 May; 22(5):374-9. PubMed ID: 15901287
[TBL] [Abstract][Full Text] [Related]
8. Long-term bosentan in chronic thromboembolic pulmonary hypertension.
Seyfarth HJ; Hammerschmidt S; Pankau H; Winkler J; Wirtz H
Respiration; 2007; 74(3):287-92. PubMed ID: 16699254
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of bosentan therapy on cardiac function and symptomatic benefits in adult patients with Eisenmenger syndrome.
Kaya MG; Lam YY; Erer B; Ayhan S; Vatankulu MA; Nurkalem Z; Meric M; Eren M; Eryol NK
J Card Fail; 2012 May; 18(5):379-84. PubMed ID: 22555267
[TBL] [Abstract][Full Text] [Related]
10. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease.
Schuuring MJ; Bouma BJ; Cordina R; Gatzoulis MA; Budts W; Mullen MP; Vis JC; Celermajer D; Mulder BJ
Int J Cardiol; 2013 Mar; 164(1):106-10. PubMed ID: 21763017
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.
Galiè N; Rubin Lj; Hoeper M; Jansa P; Al-Hiti H; Meyer G; Chiossi E; Kusic-Pajic A; Simonneau G
Lancet; 2008 Jun; 371(9630):2093-100. PubMed ID: 18572079
[TBL] [Abstract][Full Text] [Related]
12. Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study.
Wilkins MR; Paul GA; Strange JW; Tunariu N; Gin-Sing W; Banya WA; Westwood MA; Stefanidis A; Ng LL; Pennell DJ; Mohiaddin RH; Nihoyannopoulos P; Gibbs JS
Am J Respir Crit Care Med; 2005 Jun; 171(11):1292-7. PubMed ID: 15750042
[TBL] [Abstract][Full Text] [Related]
13. Treatment of secondary pulmonary hypertension with bosentan after left ventricular assist device implantation.
LaRue SJ; Garcia-Cortes R; Nassif ME; Vader JM; Ray S; Ravichandran A; Rasalingham R; Silvestry SC; Ewald GA; Wang IW; Schilling JD
Cardiovasc Ther; 2015 Apr; 33(2):50-5. PubMed ID: 25759010
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
Durongpisitkul K; Jakrapanichakul D; Sompradikul S
J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
[TBL] [Abstract][Full Text] [Related]
16. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
17. Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure.
Jiang BH; Tardif JC; Shi Y; Dupuis J
Eur Respir J; 2011 Mar; 37(3):578-86. PubMed ID: 20595149
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Channick RN; Simonneau G; Sitbon O; Robbins IM; Frost A; Tapson VF; Badesch DB; Roux S; Rainisio M; Bodin F; Rubin LJ
Lancet; 2001 Oct; 358(9288):1119-23. PubMed ID: 11597664
[TBL] [Abstract][Full Text] [Related]
19. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
[TBL] [Abstract][Full Text] [Related]
20. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients.
Gan CT; Holverda S; Marcus JT; Paulus WJ; Marques KM; Bronzwaer JG; Twisk JW; Boonstra A; Postmus PE; Vonk-Noordegraaf A
Chest; 2007 Jul; 132(1):11-7. PubMed ID: 17625080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
